Ertapenem

Structural formula
General
Non-proprietary name	Ertapenem
other names	Invance; (4 R , 5 S , 6 S ) -3 - [(3 S , 5 S ) -5 - [(3-carboxyphenyl) carbamoyl] pyrrolidin-3-yl] sulfanyl-6- (1-hydroxyethyl) -4- methyl-7-oxo-1-azabicyclo [3.2.0] hept-2-en-2-carboxylic acid;
Molecular formula	C 22 H 25 N 3 O 7 S
External identifiers / databases
PubChem	150610
ChemSpider	132758
DrugBank	DB00303
Wikidata	Q553220
Drug information
ATC code	J01 DH03
Drug class	β-lactam antibiotics , carbapenems
Mechanism of action	Inhibition of cell wall synthesis
properties
Molar mass	475.516 g / mol
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ertapenem is a drug that belongs to the group of carbapenems .

pharmacology

Ertapenem is administered parenterally and is approved for adults and children from the age of 3 months for the treatment of infections in the abdomen, community-acquired pneumonia, and gynecological infections and infections of the foot in diabetics .

Corresponding to the mode of action of the older carbapenems , ertapenem is also rapidly acting bactericidal and shows time-dependent killing kinetics; this means that a minimally effective concentration in the body must be exceeded permanently. It is stable to almost all beta -lactamases , including the "AmpC- cephalosporinase " and the extended-spectrum -β-lactamases (ESBL); in contrast to imipenem also against dehydropeptidase I.

Spectrum of activity

As a carbapenem, ertapenem is effective against both gram-positive and negative bacteria as well as against some anaerobes , but has a narrower spectrum compared to its predecessors. Ertapenem is ineffective against Pseudomonas aeruginosa and Enterococcus . In general, meropenem and ertapenem work somewhat better than imipenem in the gram-negative range .

Side effects

The side effects largely correspond to those of penicillins and cephalosporins .

Trade names

Invanz (EU, CH)

Web links

Information on Invanz on the website of the European Medicines Agency

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ KM Papp-Wallace, A. Endimiani, MA Taracila, RA Bonomo: Carbapenems: past, present, and future. In: Antimicrob Agents Chemother . 55 (11), Nov 2011, pp. 4943-4960.
↑ A. Parakh, S. Krishnamurthy, M. Bhattacharya: Ertapenem. In: Kathmandu Univ Med J (KUMJ). 7 (28), October-December 2009, pp. 454-460.
↑ BL Congeni: Ertapenem. In: Expert Opin Pharmacother . 11 (4), Mar 2010, pp. 669-672.

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] KM Papp-Wallace, A. Endimiani, MA Taracila, RA Bonomo: Carbapenems: past, present, and future. In: Antimicrob Agents Chemother . 55 (11), Nov 2011, pp. 4943-4960.

[3] A. Parakh, S. Krishnamurthy, M. Bhattacharya: Ertapenem. In: Kathmandu Univ Med J (KUMJ). 7 (28), October-December 2009, pp. 454-460.

[4] BL Congeni: Ertapenem. In: Expert Opin Pharmacother . 11 (4), Mar 2010, pp. 669-672.